News – Page 814 – Endpoints News

SIGN UP

Novartis’ star cancer drug lands on an inside FDA track, racing Lilly to a showdown with Pfizer

7 years ago

Baxalta in hand, Shire dumps drug programs in hunt for $210M in R&D cuts

7 years ago

A few key reasons why Biogen has now become a buzzed about takeover target

7 years ago

Protocols: Troubled Telesta axes staff in wake of FDA rejection; Evelo partners with Mayo researchers

7 years ago

Biotech vet MacKay grabs a $25M A round to back a gene therapy upstart

7 years ago

BioRegnum: The miracle drug story that just won’t die

7 years ago

Amgen barrels into a $540M immunotherapy deal with Advaxis

7 years ago

Regeneron leaps into the blockbuster race to develop off-the-shelf immune cell cancer therapies

7 years ago

Pfizer boosts its gene therapy work, bags upstart Bamboo in $645M buyout deal

7 years ago

Protocols: Private equity buy-in values inVentiv at $3.8B; Celgene denies charity scheme allegations

7 years ago

Microcap MEI joins the long lineup of cancer biopharmas to land a ‘breakthrough’

7 years ago

Biogen, Ionis declare an early victory for PhIII spinal muscular atrophy study, triggering $75M payout

7 years ago

Ex-Allergan CEO David Pyott backs a biotech startup alongside Takeda, PhI trial set to launch

7 years ago

Google’s Verily and GlaxoSmithKline hatch a $713M plan to spark a biorevolution

7 years ago

Tokai quickly tosses most of its staff after PhIII cancer drug fails

7 years ago

Protocols: BU’s Outterson helms $350M antibiotics project; Adaptimmune lands on EMA’s inside track

7 years ago

Bristol-Myers takes a commanding lead over Merck in the first stretch of a blockbuster race

7 years ago

Takeda overhauls R&D, focusing on Boston and Japan in global reorganization

7 years ago

NewLink axes 100 staffers, shrinks pipeline in wake of a PhIII debacle

7 years ago

Hey, wait a second. What about Roche’s PhIII hemophilia A drug?

7 years ago

Microbiome pioneer Seres crushed as lead drug flops in PhII

7 years ago

The biopharma week in review: Thumbs Up, Thumbs Down

7 years ago

Protocols: Editas gets a gene editing collaborator; Regulus hustling up response to clinical hold; Sanofi drug OK’d

7 years ago

From boom to swoon: Biotech IPOs fade fast in Q2

7 years ago

First page Previous page 811 812 813814815 816 817 Next page Last page